Akero Therapeutics Inc

NASDAQ: AKRO
$21.02
-$1.00 (-4.5%)
Closing price May 8, 2024

AKRO Chart and Intraday Price

AKRO Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 170 HARBOR WAY, SOUTH SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,549.29M USD
Shares Outstanding 55,710,000
Akero Therapeutics Inc is a biotechnology firm focused on creating treatments for serious metabolic diseases, with a spotlight on metabolic dysfunction-associated steatohepatitis (MASH). Their leading product, efruxifermin, is advancing through Phase 3 clinical trials, aiming to regulate metabolism and protect against cellular stress. Originating as Pippin Pharmaceuticals and rebranded in 2018, Akero has partnered with Amgen Inc. for the development and distribution of its treatments. The company is based in South San Francisco, California, and was established in 2017.

AKRO Articles

What Has Insiders Eyeing This Biotech Stock
A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider buying too.
Trey Thoelcke
Published: